A prospective evaluation of plasma phospholipid fatty acids and breast cancer risk in the EPIC study
dc.contributor.author | Chajès, Véronique | |
dc.contributor.author | Assi, Nada | |
dc.contributor.author | Biessy, Carine | |
dc.contributor.author | Ferrari, P. | |
dc.contributor.author | Rinaldi, Sabina | |
dc.contributor.author | Slimani, Nadia | |
dc.contributor.author | Lenoir, GM | |
dc.contributor.author | Baglietto, L | |
dc.contributor.author | His, Mathilde | |
dc.contributor.author | Boutron-Ruault, M.C. | |
dc.contributor.author | Trichopoulou, A | |
dc.contributor.author | Lagiou, P. | |
dc.contributor.author | Katsoulis, M | |
dc.contributor.author | Kaaks, R. | |
dc.contributor.author | Kuhn, T. | |
dc.contributor.author | Panico, S. | |
dc.contributor.author | Pala, V | |
dc.contributor.author | Masala, G | |
dc.contributor.author | Bueno-De-Mesquita, Hendrik Bastiaan | |
dc.contributor.author | Peeters, P.H. | |
dc.contributor.author | van Gils, Carla | |
dc.contributor.author | Hjartåker, Anette | |
dc.contributor.author | Olsen, Karina Standahl | |
dc.contributor.author | Borgund Barnung, Runa | |
dc.contributor.author | Barricarte, A | |
dc.contributor.author | Redondo-Sánchez, Daniel | |
dc.contributor.author | Menéndez, V | |
dc.contributor.author | Amiano, P. | |
dc.contributor.author | Wennberg, Maria | |
dc.contributor.author | Key, T. | |
dc.contributor.author | Khaw, K.T. | |
dc.contributor.author | Merritt, M.A. | |
dc.contributor.author | Riboli, E. | |
dc.contributor.author | Gunter, M.J. | |
dc.contributor.author | Romieu, I. | |
dc.date.accessioned | 2018-09-06T09:25:01Z | |
dc.date.available | 2018-09-06T09:25:01Z | |
dc.date.issued | 2017-09-18 | |
dc.description.abstract | <p><i>Background</i>: Intakes of specific fatty acids have been postulated to impact breast cancer risk but epidemiological data based on dietary questionnaires remain conflicting.</p> <p><i>Materials and methods</i>: We assessed the association between plasma phospholipid fatty acids and breast cancer risk in a case–control study nested within the European Prospective Investigation into Cancer and Nutrition study. Sixty fatty acids were measured by gas chromatography in pre-diagnostic plasma phospholipids from 2982 incident breast cancer cases matched to 2982 controls. Conditional logistic regression models were used to estimate relative risk of breast cancer by fatty acid level. The false discovery rate (q values) was computed to control for multiple comparisons. Subgroup analyses were carried out by estrogen receptor (ER) and progesterone receptor expression in the tumours.</p> <p><i>Results</i>: A high level of palmitoleic acid [odds ratio (OR) for the highest quartile compared with the lowest OR (Q4–Q1) 1.37; 95% confidence interval (CI), 1.14–1.64; P for trend = 0.0001, q value = 0.004] as well as a high desaturation index (DI16) (16:1n–7/16:0) [OR (Q4–Q1), 1.28; 95% C, 1.07–1.54; P for trend = 0.002, q value = 0.037], as biomarkers of <i>de novo</i> lipogenesis, were significantly associated with increased risk of breast cancer. Levels of industrial <i>trans</i>-fatty acids were positively associated with ER-negative tumours [OR for the highest tertile compared with the lowest (T3–T1)=2.01; 95% CI, 1.03–3.90; P for trend = 0.047], whereas no association was found for ER-positive tumours (P-heterogeneity =0.01). No significant association was found between n-3 polyunsaturated fatty acids and breast cancer risk, overall or by hormonal receptor.</p> <p><i>Conclusion</i>: These findings suggest that increased <i>de novo</i> lipogenesis, acting through increased synthesis of palmitoleic acid, could be a relevant metabolic pathway for breast tumourigenesis. Dietary <i>trans</i>-fatty acids derived from industrial processes may specifically increase ER-negative breast cancer risk. | en_US |
dc.description.sponsorship | World Cancer Research Funds The Institut National du Cancer (INCA) The European Commission The International Agency for Research on Cancer Danish Cancer Society Ligue Contre le Cancer Institut Gustave Roussy Mutuelle Générale de l’Education Nationale Institut National de la Santé et de la Recherche Médicale Deutsche Krebshilfe Deutsches Krebsforschungszentrum Federal Ministry of Education and Research The Hellenic Health Foundation Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy National Research Council Dutch Ministry of Public Health, Welfare and Sports Netherlands Cancer Registry LK Research Funds Dutch Prevention Funds Dutch ZON (Zorg Onderzoek Nederland) World Cancer Research Fund (WCRF) Statistics Netherlands (The Netherlands) UiT The Arctic University of Norway Health Research Fund (FIS) Swedish Cancer Society Swedish Scientific Council and County Councils of Skåne and Västerbotten Cancer Research UK Medical Research Council INCA | en_US |
dc.description | This is a pre-copyedited, author-produced version of an article accepted for publication in <i>Annals of Oncology</i> following peer review. The version of record Chajès, V., Assi, N., Biessy, C., Ferrari, P., Rinaldi, S., Slimani, N., ... Romieu, I. (2017). A prospective evaluation of plasma phospholipid fatty acids and breast cancer risk in the EPIC study. Annals of Oncology, 28(11), 2836-2842. https://doi.org/10.1093/annonc/mdx482, is available online at: <a href=https://doi.org/10.1093/annonc/mdx482> https://doi.org/10.1093/annonc/mdx482</a>. | en_US |
dc.identifier.citation | Chajès, V., Assi, N., Biessy, C., Ferrari, P., Rinaldi, S., Slimani, N., ... Romieu, I. (2017). A prospective evaluation of plasma phospholipid fatty acids and breast cancer risk in the EPIC study. Annals of Oncology, 28(11), 2836-2842. https://doi.org/10.1093/annonc/mdx482 | en_US |
dc.identifier.cristinID | FRIDAID 1529205 | |
dc.identifier.doi | 10.1093/annonc/mdx482 | |
dc.identifier.issn | 0923-7534 | |
dc.identifier.issn | 1569-8041 | |
dc.identifier.uri | https://hdl.handle.net/10037/13693 | |
dc.language.iso | eng | en_US |
dc.publisher | Oxford University Press (OUP) | en_US |
dc.relation.journal | Annals of Oncology | |
dc.rights.accessRights | openAccess | en_US |
dc.subject | VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762 | en_US |
dc.subject | VDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762 | en_US |
dc.subject | fatty acids | en_US |
dc.subject | biomarkers | en_US |
dc.subject | breast cancer | en_US |
dc.subject | epidemiology | en_US |
dc.subject | EPIC | en_US |
dc.subject | fatty acids | en_US |
dc.subject | diet | en_US |
dc.subject | heterogeneity | en_US |
dc.subject | biological markers | en_US |
dc.subject | phospholipids | en_US |
dc.subject | plasma | en_US |
dc.subject | breast | en_US |
dc.subject | diagnosis | en_US |
dc.subject | neoplasms | en_US |
dc.subject | breast cancer | en_US |
dc.subject | lipogenesis | en_US |
dc.subject | epic study | en_US |
dc.subject | estrogen receptor negative | en_US |
dc.subject | desaturation of blood | en_US |
dc.subject | epic trial | en_US |
dc.subject | breast cancer risk | en_US |
dc.title | A prospective evaluation of plasma phospholipid fatty acids and breast cancer risk in the EPIC study | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |
dc.type | Peer reviewed | en_US |